Dublin-based early-stage pharmaceutical company Inflazome has closed on a 40 million euros ($46 million) in Series B funding round.
Inflazome expects to use the funds to advance its first in class NLRP3 inflammasome inhibitors into multiple clinical trials in 2019, with next-generation compounds following thereafter.
Led by Dutch private equity and venture capital firm Forbion with California-based peer Longitude Capital, the funding round had initial investors, Novartis Venture Fund and Fountain Healthcare Partners, also participating.
Forbion and Longitude Capital, have joined Inflazome’s board of directors, following the completion of the financing round.